Additional approval requirement in China pains drug industry
This article was originally published in SRA
Between 50 and 60 new drugs cleared for clinical development in China face an additional layer of regulatory approval, which could further delay product approvals by 30 months, warns multinational big pharma trade group RDPAC.
You may also be interested in...
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.